SCHEMBL3526252

SCHEMBL3526252

CS(=O)(=O)N1CCC(Nc2ncc(C(=O)c3c(F)c(F)cc4ccoc34)c(N)n2)CC1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 19/20 0.73
CDK1 P06493 16/20 0.73
CCND1 P24385 16/20 0.73
CDK4 P11802 15/20 0.73
CDK6 Q00534 3/20 0.68
CDK5 Q00535 2/20 0.68
CASK O14936 1/20 0.68
ROCK2 O75116 1/20 0.68
CDKL5 O76039 1/20 0.68
STK10 O94804 1/20 0.68
CDK14 O94921 1/20 0.68
ABL1 P00519 1/20 0.68
EGFR P00533 1/20 0.68
MAK P20794 1/20 0.68
CDK11B P21127 1/20 0.68
TTK P33981 1/20 0.68
CLK1 P49759 1/20 0.68
CLK2 P49760 1/20 0.68
CLK3 P49761 1/20 0.68
GSK3A P49840 1/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3519763 0.92 CDK2 (0.63) CDK2CDK1CCND1CDK4CDK6
SCHEMBL13621492 0.88 CDK2 (0.70) CDK2CDK1CCND1CDK4CDK6
SCHEMBL3519522 0.87 CDK2 (0.68) CDK2CDK1CCND1CDK4CDK6
SCHEMBL4359143 0.87 CDK2 (0.74) CDK2CDK1CCND1CDK4CDK6
SCHEMBL4348415 0.85 CDK2 (0.80) CDK2CDK1CCND1CDK4CDK6
SCHEMBL3522558 0.84 CDK1 (1.00) CDK2CDK1CCND1CDK4CDK6
SCHEMBL4361166 0.83 CDK1 (0.78) CDK2CDK1CCND1CDK4CDK6
SCHEMBL4739451 0.83 CDK2 (0.49) CDK2CDK1CCND1CDK4CDK6
SCHEMBL3520595 0.82 CDK1 (0.79) CDK2CDK1CCND1CDK4CDK6
SCHEMBL4352866 0.81 CDK1 (0.85) CDK2CDK1CCND1CDK4CDK6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7705009-B2 4-aminopyrimidine-5-thione derivatives HOFFMAN-LA ROCHE INC. (US) 2010-04-27 US disclosed
US-7705009-B2 4-aminopyrimidine-5-thione derivatives HOFFMAN-LA ROCHE INC. (US) 2010-04-27 US disclosed
US-7705009-B2 4-aminopyrimidine-5-thione derivatives HOFFMAN-LA ROCHE INC. (US) 2010-04-27 US disclosed
WO-2007060110-A1 4-AMINOPYRIMIDINE-5-THIONE-DERIVATIVES FOR THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2007-05-31 WO disclosed
US-20070117821-A1 4-Aminopyrimidine-5-thione derivatives DING QINGJIE 2007-05-24 US disclosed
US-20070117821-A1 4-Aminopyrimidine-5-thione derivatives DING QINGJIE 2007-05-24 US disclosed
US-20070117821-A1 4-Aminopyrimidine-5-thione derivatives DING QINGJIE 2007-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070117821-A1 4-Aminopyrimidine-5-thione derivatives CDK4, CDK1, CDK2 CDK2 3/4885CDK1 2/4885CCND1 40/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.